EWINGS TUMORS WITH PRIMARY LUNG METASTASES - SURVIVAL ANALYSIS OF 114(EUROPEAN INTERGROUP) COOPERATIVE EWINGS-SARCOMA STUDIES PATIENTS

Citation
M. Paulussen et al., EWINGS TUMORS WITH PRIMARY LUNG METASTASES - SURVIVAL ANALYSIS OF 114(EUROPEAN INTERGROUP) COOPERATIVE EWINGS-SARCOMA STUDIES PATIENTS, Journal of clinical oncology, 16(9), 1998, pp. 3044-3052
Citations number
32
Categorie Soggetti
Oncology
ISSN journal
0732183X
Volume
16
Issue
9
Year of publication
1998
Pages
3044 - 3052
Database
ISI
SICI code
0732-183X(1998)16:9<3044:ETWPLM>2.0.ZU;2-N
Abstract
Purpose: To analyze event-free survival (EFS) and prognostic factors i n patients who present with Ewing's tumors (ET) of bone and synchronou s pulmonary and/or pleural metastases (ppm). Patients and Methods: Of l,270 patients (pts) registered at the continental office of the Germa n/European Intergroup Cooperative Ewing's Sarcoma Studies (CESS81, CES S86, EICESS92), 114 were diagnosed ET with ppm. patients underwent neo adjuvant therapy and local treatment of the primary tumor. Whole-lung irradiation 15 to 18 Gy was applied to 75 ppm-pts, EFS and 95% confide nce intervals (CIs) were estimated according to the Kaplan Meier metho d, and prognostic factors were analyzed by log-rank tests and Cox and logistic regression procedures.Results: On November 1, 1997, at a medi an time under study of 5.9 years, the 5 year EFS was 0.36 (95% CI, 0.2 6 to 0.46) and the 10-year EFS was 0.30 (95% CI, 0.19 to 0.41), Thirty -seven of 59 (63%) first relapses involved lung and/or pleura, and the lungs were the only site of relapse in 26 of 59 (44%) ppm-pts, Risk f actors identified in univariate and multivariate tests were poor respo nse of the primary tumor toward chemotherapy, metastatic lesions in bo th lungs, and treatment without additional lung irradiation. Conclusio n: Chemotherapy response of the primary tumor is a prognostic factor i n patients with ET with ppm. Strategies of treatment intensification w arrant further evaluation. J Clin Oncol 16:3044-3052, (C) 1998 by Amer ican Society of Clinical Oncology.